Insulet Corp (PODD) Stock Price & Analysis
Insulet Corp (PODD) rose 5.35% to USD 159.61 as of June 9, 2026 at 23:39 UTC, according to Nexqual real-time market data.
PODD last closed at USD 151.51; the session ranged USD 149.17–160.87 on volume of 1,818,914 shares. Market capitalization is $11.06B, with a 52-week range of USD 140.63–354.88 (NMS). Source: Nexqual, June 9, 2026 at 23:39 UTC.
Key Statistics (as of June 9, 2026 at 23:39 UTC)
| Price | USD 159.61 |
|---|---|
| Change | ▲ 5.35% (up) |
| Previous Close | USD 151.51 |
| Open | USD 150.92 |
| Day Range | USD 149.17 – 160.87 |
| 52-Week Range | USD 140.63 – 354.88 |
| Volume | 1,818,914 shares |
| Market Cap | $11.06B |
| Exchange | NMS |
Technical Analysis (PODD)
Nexqual's technical model rates PODD "SELL" based on 2 bullish and 4 bearish signals across 124 daily candles, as of June 9, 2026 at 23:39 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 49.57 (neutral) |
| vs SMA50 | Below (USD 173.17) |
| MACD | -6.1 (negative) |
Analyst Ratings (PODD)
Wall Street analysts rate PODD "Strong Buy" based on 23 analysts, with a mean price target of USD 243.78 (range USD 165–360), per Nexqual as of June 9, 2026 at 23:39 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 23 |
| Mean Target | USD 243.78 |
| High Target | USD 360 |
| Low Target | USD 165 |
| Buy / Hold / Sell | 21 / 3 / 0 |
Earnings (PODD)
| Next Earnings Date | 2026-08-06 |
|---|---|
| EPS Estimate | USD 1.45 |
| Revenue Estimate | $787.82M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 1.42 vs est 1.19 ▲ beat |
| 2025-12-31 | USD 1.55 vs est 1.46 ▲ beat |
| 2025-09-30 | USD 1.24 vs est 1.15 ▲ beat |
| 2025-06-30 | USD 1.17 vs est 0.92 ▲ beat |
Source: Nexqual, June 9, 2026 at 23:39 UTC.
Financials & Fundamentals (PODD)
| Total Revenue | $2.90B |
|---|---|
| Revenue Growth (YoY) | +33.90% |
| Gross Margin | +71.01% |
| Operating Margin | +16.03% |
| Profit Margin | +10.44% |
| ROE | +23.00% |
| Debt / Equity | 77.84 |
| Current Ratio | 2.49 |
| Total Cash | $480.40M |
| Total Debt | $1.01B |
| Free Cash Flow | $253.38M |
Source: Nexqual, June 9, 2026 at 23:39 UTC.
Financial Health Score (PODD)
Nexqual rates Insulet Corp's overall financial health "Strong" across five dimensions, as of June 9, 2026 at 23:39 UTC.
| Growth | Strong — Revenue +31% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 71%, operating 16% |
| Balance Sheet | Mixed — $480M cash vs $1.01B debt |
| Cash Flow | Solid — FCF $253M, 9% margin |
| Efficiency | Strong — ROE 23%, ROA 9.7% |
Ownership (PODD)
| Insider Ownership | +0.33% |
|---|---|
| Institutional Ownership | +105.55% |
| Shares Outstanding | 69.26M |
| Float | 68.99M |
| Short % of Float | +4.91% |
Source: Nexqual, June 9, 2026 at 23:39 UTC.
Leadership (PODD)
Insulet Corp is led by Ashley A. McEvoy (age 54), CEO, President & Director, per Nexqual as of June 9, 2026 at 23:39 UTC.
| CEO, President & Director | Ashley A. McEvoy (age 54) |
|---|---|
| Executive VP & CFO | Flavia H. Pease (age 52) |
| Executive VP & COO | Eric Benjamin (age 42) |
| Senior Vice President of Global Operations | Prem Singh (age 48) |
| Senior VP & CTO | Amit Guliani |
Major Backers & Investors (PODD)
Notable institutional backers of Insulet Corp include FMR, LLC, T. Rowe Price, Baillie Gifford, according to Nexqual as of June 9, 2026 at 23:39 UTC.
Active Investors
| Investor | Stake |
|---|---|
| FMR, LLC | 5.74% |
| T. Rowe Price | 3.87% |
| Baillie Gifford | 2.93% |
| Fidelity | 2.58% |
| Capital Group | 2.41% |
| AQR Capital Management, LLC | 2.31% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 19.68% |
| BlackRock | 10.52% |
| State Street | 5.6% |
| Geode Capital | 2.92% |
Source: Nexqual, June 9, 2026 at 23:39 UTC.
From Insulet Corp's Latest SEC 10-K Filing (filed 2026-02-18)
Key Strengths & Strategy (as disclosed to the SEC)
- As a medical device manufacturer and distributor, our manufacturing facilities and the facilities of our suppliers are subject to periodic inspection by the FDA, certain corresponding state agencies, and other regulatory bodies. 7 Table of Contents Intellectual Property To maintain a competitive advantage, we believe we must develop and preserve the proprietary aspect of our technologies.
- Our Omnipod platform's unique patented design allows us to provide Pod therapy at a relatively low or no up-front investment, which reduces the risk to third-party payors in the United States.
- We rely on a combination of copyright, patent, trademark, trade secret, and other intellectual property laws, non-disclosure agreements, and other measures to protect our proprietary rights.
- Patents As of December 31, 2025, we had over 1,000 patents in the United States and certain other countries, with expiration dates ranging from 2026 through 2047 and had over 700 patent applications pending.
Partnerships
- Data Management We have partnered with Glooko Inc. ("Glooko") to connect user data with Glooko's comprehensive diabetes data management system (including Diasend in selected regions).
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| DXCM | DexCom, Inc. | USD 78.19 | ▲ 7.32% |
| TNDM | Tandem Diabetes Care, Inc. | USD 17.61 | ▼ 8.95% |
| PEN | Penumbra, Inc. | USD 321.06 | ▲ 0.17% |
| MASI | Masimo Corporation | USD 179.95 | ▲ 0.63% |
| RMD | ResMed Inc. | USD 196.94 | ▲ 0.46% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 9, 2026 at 23:39 UTC. This page is informational and not investment advice.